Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Fate Therapeutics (NQ: FATE ) 3.540 +0.020 (+0.57%) Streaming Delayed Price Updated: 4:00 PM EDT, May 28, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Fate Therapeutics < Previous 1 2 3 4 Next > Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates May 09, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program May 09, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates May 06, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Fate Therapeutics Inc. (NASDAQ: FATE) Near the Top of Equities by Percentage Gain on 9/18 September 18, 2023 Via Investor Brand Network Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting May 03, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting April 22, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference April 03, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) April 02, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement March 19, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) March 05, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Fate Therapeutics to Present at Upcoming March Investor Conferences March 01, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates February 26, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results February 15, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) February 02, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors January 08, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) December 13, 2023 From Fate Therapeutics, Inc. Via GlobeNewswire Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates November 08, 2023 From Fate Therapeutics, Inc. Via GlobeNewswire FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm November 03, 2023 From Bragar Eagel & Squire Via GlobeNewswire Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results October 25, 2023 From Fate Therapeutics, Inc. Via GlobeNewswire Fate Therapeutics to Present at Upcoming September Investor Conferences August 31, 2023 From Fate Therapeutics, Inc. Via GlobeNewswire FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm August 27, 2023 From Bragar Eagel & Squire Via GlobeNewswire Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates August 08, 2023 From Fate Therapeutics, Inc. Via GlobeNewswire Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results July 28, 2023 From Fate Therapeutics, Inc. Via GlobeNewswire FATE THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Fate Therapeutics, Inc. - FATE June 30, 2023 From Kahn Swick & Foti, LLC Via Business Wire FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm June 21, 2023 From Bragar Eagel & Squire, P.C. Via Business Wire Fate ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm June 08, 2023 From Bragar Eagel & Squire, P.C. Via Business Wire FATE THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Fate Therapeutics, Inc. - FATE June 05, 2023 From Kahn Swick & Foti, LLC Via Business Wire Fate Therapeutics to Present at Upcoming June Investor Conferences May 31, 2023 From Fate Therapeutics, Inc. Via GlobeNewswire NASDAQ:FATE Long Term Investor Alert: Investigation of Potential Wrongdoing at Fate Therapeutics, Inc. May 24, 2023 San Diego, CA -- (SBWIRE) -- 05/24/2023 -- An investigation was announced for investors in shares of Fate Therapeutics, Inc. (NASDAQ:FATE) concerning potential breaches of fiduciary duties by certain... Via SBWire Fate Therapeutics Reports First Quarter 2023 Financial Results and Business Updates May 03, 2023 From Fate Therapeutics, Inc. Via GlobeNewswire < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.